--- title: "Monopar Therapeutics (MNPR) news: offering" url: "https://aibio.space/companies/monopar-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "MNPR offering news: Monopar Therapeutics agrees to sell 798,655 shares at $23.79 plus pre-funded warrants. Monopar Therapeutics Inc." --- MNPR Monopar Therapeutics Inc. NASDAQ · United States # Monopar Therapeutics (MNPR) news MNPR offering news Financings · 2024-12-23 ## [Monopar Therapeutics agrees to sell 798,655 shares at $23.79 plus pre-funded warrants](https://aibio.space/news/monopar-therapeutics-agrees-sell-798-655-shares-23-79-plus-pre-funded/) The underwritten offering and a concurrent private placement are expected to bring net proceeds of about $37.6 million. ## Latest Monopar Therapeutics news We have not published a story on Monopar Therapeutics yet. When there is news, it will appear here. ## Monopar Therapeutics at a glance - **Ticker**: MNPR - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $105.4 million ### Related companies - [DiaMedica Therapeutics](https://aibio.space/companies/diamedica-therapeutics/) NASDAQ: DMAC - [Prelude Therapeutics](https://aibio.space/companies/prelude-therapeutics/) NASDAQ: PRLD - [Nkarta](https://aibio.space/companies/nkarta/) NASDAQ: NKTX - [X4 Pharmaceuticals](https://aibio.space/companies/x4-pharmaceuticals/) NASDAQ: XFOR - [Stoke Therapeutics](https://aibio.space/companies/stoke-therapeutics/) NASDAQ: STOK - [Neutra](https://aibio.space/companies/neutra/) OTC: NTRR - [Xeris Biopharma Holdings](https://aibio.space/companies/xeris-biopharma/) NASDAQ: XERS - [XBiotech](https://aibio.space/companies/xbiotech/) NASDAQ: XBIT ### Also on NASDAQ - [Avalo Therapeutics](https://aibio.space/companies/avalo-therapeutics/) AVTX - [Actuate Therapeutics](https://aibio.space/companies/actuate-therapeutics/) ACTU - [GT Biopharma](https://aibio.space/companies/gt-biopharma/) GTBP - [Dyne Therapeutics](https://aibio.space/companies/dyne-therapeutics/) DYN - [Traws Pharma](https://aibio.space/companies/traws-pharma/) TRAW - [AbCellera Biologics](https://aibio.space/companies/abcellera-biologics/) ABCL ## Monopar Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$0](https://www.sec.gov/Archives/edgar/data/1645469/000143774926010025/) | [$0](https://www.sec.gov/Archives/edgar/data/1645469/000143774925009979/) | | Research and development | [$9.9 million](https://www.sec.gov/Archives/edgar/data/1645469/000143774926010025/) | [$13.0 million](https://www.sec.gov/Archives/edgar/data/1645469/000143774926010025/) | | Net income (loss) | [-$13.7 million](https://www.sec.gov/Archives/edgar/data/1645469/000143774926010025/) | [-$15.6 million](https://www.sec.gov/Archives/edgar/data/1645469/000143774926010025/) | | Cash from operations | [-$12.2 million](https://www.sec.gov/Archives/edgar/data/1645469/000143774926010025/) | [-$6.4 million](https://www.sec.gov/Archives/edgar/data/1645469/000143774926010025/) | | Cash and equivalents | [$61.8 million](https://www.sec.gov/Archives/edgar/data/1645469/000143774926027164/) | [$45.8 million](https://www.sec.gov/Archives/edgar/data/1645469/000143774926010025/) | | Short-term investments | [$60.9 million](https://www.sec.gov/Archives/edgar/data/1645469/000143774926027164/) | [$45.5 million](https://www.sec.gov/Archives/edgar/data/1645469/000143774926010025/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $52.8 million, plus short-term investments of $52.6 million, $105.4 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Monopar Therapeutics Has Monopar Therapeutics raised money recently? Our latest story on this, dated Dec 23, 2024: "Monopar Therapeutics agrees to sell 798,655 shares at $23.79 plus pre-funded warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/monopar-therapeutics-agrees-sell-798-655-shares-23-79-plus-pre-funded/). What is the ticker symbol of Monopar Therapeutics? Monopar Therapeutics Inc. trades under the ticker MNPR on NASDAQ. Where is Monopar Therapeutics listed? Monopar Therapeutics Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:1IY0. What is the SEC CIK of Monopar Therapeutics? The SEC Central Index Key (CIK) for Monopar Therapeutics Inc. is 1645469. Its filings are on SEC EDGAR. How many shares does Monopar Therapeutics have outstanding? 6,712,172 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Monopar Therapeutics listed under? Our directory records Monopar Therapeutics Inc. under United States. What does Monopar Therapeutics do? Our directory classifies Monopar Therapeutics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Monopar Therapeutics? The ISIN recorded for Monopar Therapeutics Inc. is US61023L2079. Does aibio.space cover Monopar Therapeutics? aibio.space lists Monopar Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Monopar Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What was Monopar Therapeutics's revenue last year? $0 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Monopar Therapeutics profitable? Monopar Therapeutics Inc. reported a net loss of $13.7 million for the fiscal year ended Dec 31, 2025, and used $12.2 million of cash in operations, per its annual report to the SEC. How much does Monopar Therapeutics spend on research and development? $9.9 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Monopar Therapeutics have? $105.4 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Monopar Therapeutics (MNPR) stock news? Our latest story on Monopar Therapeutics, dated Dec 23, 2024: "Monopar Therapeutics agrees to sell 798,655 shares at $23.79 plus pre-funded warrants". The underwritten offering and a concurrent private placement are expected to bring net proceeds of about $37.6 million. [Source](https://aibio.space/news/monopar-therapeutics-agrees-sell-798-655-shares-23-79-plus-pre-funded/). ## Investor discussion: Monopar Therapeutics Members talk about Monopar Therapeutics (MNPR). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Monopar Therapeutics, newest first. Each line links the filing it comes from. 1. 2025-09-24 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1645469/000143774925029769/mnpr20250924_424b5.htm) 2. 2024-12-23 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1645469/000143774924038213/mnpr20241220_424b5.htm) 3. 2024-11-29 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1645469/000143774924036380/mnpr20241126_s3.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:MNPR on TradingView](https://www.tradingview.com/symbols/NASDAQ-MNPR/). ## SEC filings and registration - **SEC name**: Monopar Therapeutics - **CIK**: 1645469 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: MNPR (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 1000 SKOKIE BLVD SUITE 350, WILMETTE, IL, 60091 - **Phone**: 8473880349 - **Shares outstanding**: 6,712,172 as of 2026-07-31 (10-Q filed 2026-08-12) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1645469/000143774926027165/mnpr20260811_8k.htm) filed 2026-08-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/1645469/000143774926027164/mnpr20260630_10q.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1645469/000143774926024041/mnpr20260721_8k.htm) filed 2026-07-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1645469/000143774926022086/mnpr20260629_8k.htm) filed 2026-06-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1645469/000143774926021832/mnpr20260625_8k.htm) filed 2026-06-26 - [8-K](https://www.sec.gov/Archives/edgar/data/1645469/000143774926021350/mnpr20260622_8k.htm) filed 2026-06-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1645469/000143774926018896/mnpr20260529_8k.htm) filed 2026-05-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1645469/000143774926017821/mnpr20260513_8k.htm) filed 2026-05-19 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001645469), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Monopar Therapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MNPR, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Monopar Therapeutics Inc. - **Ticker**: MNPR - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US61023L2079 - **Other listed symbols**: GETTEX:1IY0 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-MNPR/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/monopar-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Monopar Therapeutics (MNPR) news: offering", 2026-10-31, https://aibio.space/companies/monopar-therapeutics/